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Chapter 1/ Introduction 
 
Pregnancy has commonly been viewed as a cooperative interaction between a mother and 
her fetus [1]. This interaction is carried out entirely by the placenta. It is defined as a 
complex organ that facilitates physiologic exchange between the developing fetus and its  
mother and it is fundamental for pregnancy success or failure [2].    
The eutherian (mammalian) placenta varies dramatically among species due to high 
anatomical diversity, such as differences in placental shape, number of layers of 
trophoblasts, shape of maternal-fetal interdigitation, the contact between fetal and 
maternal tissues and their access to maternal blood flow [3, 4]. These complex structures 
have been topic of studies for nearly 20 years  and many interpretations  have been raised in 
order to understand tracing patterns of placental evolution [5, 6].  
Actually, three main types of placental interface have been classified according to the extent 
of how the fetal tissue invades the wall of the uterus or the maternal vessels. There are 
epitheliochorial, endotheliochorial and haemochorial placentas (Fig. 1). Epitheliochorial 
placentation is considered to have three layers of maternal tissue separating the fetus from 
maternal blood and displaying poor invasiveness [3]. Important representatives are lemurs 
(lower primates), eastern moles (Scalopus), horses (Perissodactyla) and whales (Cetacea) [5]. 
The second type of placentation, endotheliochorial, is characterized by a partially invasive 
phenotype, in which only the endothelial wall of the maternal blood vessels separates the 
fetus from the maternal blood [3]. Carnivora is one of representatives of this group. Finally, 
haemochorial placentation features a range of properties that allow fetal tissues to be 
bathed directly in the maternal blood and includes a major invasion than the other two kinds 
of placentation which has the advantage of a more efficient nutrient uptake and waste 
elimination. However, this direct contact between maternal and fetal tissue implies an 
increased risk of maternal bleeding after delivery and a greater chance of fetal cell transfer 
to the maternal system [3, 4]. For instance, human and mouse placentas belong to the 
haemochorial type but the human placenta differs from mice in cell biology [7], endocrine 
system [8], immune system [9] and placental transport [10].  
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Figure 1. Models of placentation according to the extent of fetal tissue invasion into the wall of 
the uterus or the maternal vessels in eutherian species. YS: Yolk sac, E:Endometrium, ALC: 
Allantoic Cavity, AC: Amniotic cavity, C: Chorion, AM: Amnion, A: Allantois, UW: Uterine Wall, 
CV: Chorionic Villy, M: Myometrium, UM: Umbilical artery and vein, MB: Maternal blood 
supply in intervillus space, UT: Uterine artery and vein (Modified after [11]). 
 
Due to differences to other species, the human pregnancy is considered to possess great 
plasticity and has been generating exciting questions for immunologists and reproductive 
biologists for nearly 60 years. For example, the immunological situation found during 
pregnancy is considered as a paradox caused by the fact that in pregnancy the semi-
allogeneic fetus must be tolerated [12]. Another topic that produces fascination is the 
formative stages of placental development (from the time of implantation at 5 weeks of 
gestation). These are little understood because of the limited access to corresponding 
samples due to ethical and practical reasons leading to the metaphor of a “black box” for 
this period of placental development [13]. Finally, the comparatively inefficient human 
reproduction is a matter of great importance, in special for the assisted reproductive 
technologies. Fertility rates are only 20% per month and an additional third of all fertilized 
human embryos get lost during the early post-implantation period. For this reason, the 
human reproduction success is much lower than that of many other eutherian species, for 
which the estimates in primates, rodents and domestic animals are 70% [13-15]. Therefore, 
the time of implantation of the blastocyst and early development of the placenta is 
fundamental for understanding the success of human pregnancy.   
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1.1. Human implantation: “Implantation window” 
After fertilization, the embryo initiates its fast division and enters the uterine cavity at the 
morula stage (around 4 days). Subsequently, it develops into a blastocyst and then hatches 
from the zona pellucida. The free-floating blastocyst is conducted at the uterine wall in order 
to transform the endometrium for pregnancy support. Once the blastocyst is in contact with 
the endometrial epithelium (apposition), the embryonic pole is oriented to the potential 
implantation sites and fetally derived cells (trophoblasts) penetrate between the luminal 
epithelial cells at the point of attachment (adhesion), invade through the basal lamina and 
penetrate deeply into the decidualized stroma until they engraft the maternal vasculature 
(invasion). The juxtaposition of both maternal-fetal layers remodels the endometrial spiral 
arterioles into low-resistance vessels that are unable to constrict and become enlarged and 
oedematous. Then, the luminal epithelium is restored over the implantation site so that 
embryo and placenta are completely contained covered by the uterine wall and become 
highly secretory. This well-defined period of menstruation cycle is called “implantation 
window” (Fig. 2) [13, 15, 16]. 
 
 
Figure 2. Schematic diagram of blastocyst implantation to endometrium. The 
implantation involves three key phases- apposition: attachment of the blastocyst to 
the endometrium; adhesion: stable attachment; and finally invasion between luminal 
epithelial cells. (Modified after [13, 17] ). 
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Implantation induces three major consequences. First, the fetus gains direct access to its 
mother's arterial blood. Second, the volume of blood reaching the placenta becomes largely 
independent of control by the local maternal vasculature. Third, the placenta is able to 
release hormones and other substances directly into the maternal circulation for fetal 
benefit, such as chorionic gonadotropin (hCG) and human placental lactogen (hPL) [1]. 
An inappropriate invasion results in pregnancy disorders, like preeclampsia (PE) and 
increases the risk of spontaneous abortion. Therefore, a successful implantation requires 
three key factors. First of all, an embryo competent to implant; second, a receptive 
endometrium as a result of the sequential exposure of the endometrium to oestrogen 
followed by progesterone, and finally, a coordinated dialogue between endocrine, paracrine 
and juxtacrine modulators that depends on cellular and molecular crosstalk between the 
blastocyst and the receptive endometrium. This dialogue is mediated by local factors, 
including hormones, cytokines, prostaglandins and adhesion molecules, and results in local 
changes in the epithelium which permit the attachment of the embryo [15].  
 
1.2. Trophoblast Cells and Human Choriocarcinoma 
Trophoblast cells are a very heterogeneous cell type originating from a stem cell population 
which continuously proliferate and differentiate into extravillous trophoblasts or 
syncytiotrophoblast. They display numerous functions. A major function is anchoring the 
conceptus in the uterus, which trophoblast cells fulfil due to their ability to invade the 
maternal decidual tissue. A similar capacity can be also observed in cancerous tumor cells 
providing certain analogy between these two cell types. In other words, trophoblast cells use 
similar molecular mechanisms as tumors for migration and invasion [18, 19]. However, 
trophoblast invasion is limited in time and space while in cancerous tumor cells it is de-
regulated [20]. 
Another joint characteristic of trophoblast and tumor cells is the capacity of protecting 
themselves from the maternal or host immune system and thus to escape from potentially 
detrimental immunological responses from the mother or the host [16]. These properties 
are fundamental to consider trophoblast cells as an optimal candidate for studying invasive 
behavior and the molecular mechanisms applicable to pregnancy and cancer. Based on this 
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knowledge, it may be possible in future to define molecules potentially useful in cancer 
prevention or treatment as well as in pregnancy disorders. The underlying intracellular 
mechanisms and most signaling pathways remain only partially understood. 
 
1.3. Cytokines and growth factors 
Cytokines are a family of specific extra-cellular ligands, which use several distinct 
intracellular signaling pathways. They can control trophoblast behavior by either modulating 
proliferation or migration or inducing trophoblast cells to differentiate into a non-invasive 
phenotype [16, 21]. Cytokines stimulate biological responses by binding to, and activating a 
family of structurally and functionally conserved cytokine receptors [22]. This event triggers 
receptor homodimerization [23], heterodimerization or oligomerization of receptor subunits 
[24], or it induces a conformational change in preformed receptor dimers [25], which, e.g., 
results in the activation of Janus kinases (JAKs).  
Growth factors correspond to a family of secreted signaling proteins that act as initiators of 
signaling cascades in cells by paracrine and endocrine interactions. They are capable of 
inducing a variety of cellular processes and can be classified according to both structural and 
evolutionary associations, ordering them into larger families of proteins [26].  
Several cytokines and growth factors have been studied in the field of reproductive medicine 
some of which play a pivotal role. They include Interleukin-6 (IL-6), Oncostatin M (OSM), IL-
11, Hepatocyte Growth Factor (HGF), Leukemia Inhibitory Factor (LIF), Granulocyte 
macrophage-colony stimulating factor (GM-CSF) and Epidermal Growth Factor (EGF). These 
cytokines use the Janus Kinase/Signal Transducer and Activators of Transcription (JAK/STAT) 
pathway, and thereby, influence cell invasion, proliferation, differentiation, migration and 
apoptosis [16, 27]. 
 
1.3.1. Epidermal Growth Factor (EGF) 
Epidermal Growth Factor (EGF) plays an important role for embryo implantation, trophoblast 
differentiation and endocrine functions of the placenta [28, 29]. Several studies based on 
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different cell models have demonstrated that EGF influences positively or negatively a 
variety of fundamental cell properties like proliferation [30-32], differentiation [32], 
inhibition of apoptosis [33-36], motility [37-39], secretion [40, 41], angiogenesis [29] and 
invasion/ migration [37, 42-44]. However, the role of EGF on regulation of trophoblast 
behavior and the intracellular mechanisms responsible for these effects remain poorly 
understood.  
EGF binds to its cell surface receptor (EGFR) where it induces receptor dimerization and 
cross-phosphorylation. This leads to assembling of a signaling complex composed of 
cytoplasmic enzymes and adaptor proteins. The subsequent dissociation of this complex 
releases activated effector and adapter proteins into the cytoplasm where they stimulate a 
variety of intracellular pathways [45]. These cascades include phosphoinositol 3-kinase/Akt 
(PI3K/AKT), mitogen-activated protein kinase (MAPK), Phospholipase C-γ/protein kinase C 
(PLCγ /PKC), transcription factor AP-2α, ETS2 and the JAK/STAT cascade [46, 47] (Fig. 3). 
Cross-talks between the JAK/STAT and MAPK pathways in trophoblastic cells have been 
described [27, 48]. 
 
Figure 3. The main downstream signaling pathways regulated by EGFR. Upon binding of its 
ligands, EGFR homodimerizes leading to phosphorylation of many tyrosine residues localized in 
the carboxy-terminal tail of EGFR. Phospho-EGFR is then able to recruit adaptor proteins. 
Important signaling pathways regulated by EGFR are represented with important functions 
highlighted in coloured boxes. The signaling cascade does not include all the known 
components of a given pathway, and cross-talk is not shown for clarity (Taken from [49]). 
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1.4. Classical signaling pathways: JAK/STAT pathway 
The JAK/STAT signal transduction pathway is composed by five steps. Initially, the cytokine 
and receptor binding leads to the juxtaposition of receptor associated JAKs. Then, these JAKs 
become phosphorylated and activate each other and the inner receptor ligand (2nd step). 
Subsequently, STATs bind to inner receptors to be phosphorylated and activated by JAKs (3rd 
step). When STATs are activated, they dissociate from the receptor and form homo- and 
heterodimers. Finally, these dimers translocate into the nucleus and promote transcriptional 
activation of cytokine inducible genes (4th and 5th) (Fig. 4). Thus the JAK/STAT cascade 
provides a direct mechanism to translate an extracellular signal into a transcriptional 
response [16, 50, 51].  
 
 
Figure 4. JAK/STAT pathway. 1). Cytokine binding leads to receptor aggregation; 2) JAKs 
phosphorylate and activate each other and inner receptor ligand; 3) STATs bind to inner 
receptor ligand to be activated by JAKs; 4) activated STATs disassociate to from homo- and 
heterodimers and translocate into the nucleus to accelerate transcription of target proteins; 5) 
one target protein family are SOCSs which limit further STAT activation by binding to JAKs 
(Taken from [16]). 
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The family of JAKs is characterized by large tyrosine kinases that include JAK1, JAK2, JAK3 
and Tyk2. These proteins are cytoplasmic tyrosine kinases that consist of seven different 
domains and whose functions are complex and still being elucidated [51-53]. STATs are 
latent cytoplasmic transcription factors that can interact with some nuclear factors and 
coactivators, which increase the range of transcriptional responses in which STATs and its 
isoforms can participate. The STATs family comprises seven members in mammals: STAT1 to 
6, including STAT5A and STAT5B. They can be activated by partially overlapping sets of 
cytokines but different STAT molecules have non-redundant biological roles [51, 54, 55]. 
STAT3 has been extensively studied in pregnancy because of its relevance in the control of 
trophoblast proliferation and invasion [48, 56]. More recently, STAT5A and B have been 
investigated because their dysregulation is associated with pregnancy pathologies. STAT5A 
and STAT5B share 96% of their sequence but are encoded by two different genes on 
chromosome 17 [57, 58]. Each protein has its own function but they can also work 
synergistically [59, 60]. STAT5A is important for mammary gland development, augmenting 
milk protein expression on prolactin induction [58, 59], and its deficiency results in a severe 
loss of mammary gland development in mice [61]. On the other hand, STAT5B controls 
growth hormone signaling and regulates expression of sexually dimorphic genes which 
control male/female size differences in mice [59]. Additionally, lack of STAT5B is associated 
with early abortions that are due to reduced progesterone levels during midge-station. This 
effect is exacerbated in the phenotype of mice lacking both STAT5 proteins [61].  
JAK/STAT pathway was discovered roughly 20 years ago and since then, many studies have 
revealed the important role of STATs in several biological responses, including cell 
proliferation and invasion. However, the knowledge about that is not complete [51, 55]. 
Moreover, the well characterized JAK/STAT system may provide a better understanding of 
the physiological mechanisms of invasion and its control and may serve as a valuable 
paradigm for studying the architecture of gene regulatory networks. The discovery of 
untranslated or non-coding RNAs, such as microRNAs, provide an opportunity to elucidate 
their roles in such networks. These microRNAs can act as downstream effectors of the JAK-
STAT pathway and/or affect signaling by regulating the expression of JAK-STAT components. 
The dialogue between JAK/STAT cascade and microRNAs has already emerged in basic cell 
biology and human diseases, and may lead to novel molecular biomarkers and 
 9 
pharmacological strategies to interfere with cellular processes and prevention of diseases. 
[62].  
 
1.5. MicroRNAs 
The study of epigenetics has attracted attention in different fields, such as human 
reproduction and has provided important novel interpretations of genetic research. 
Epigenetics has different meanings; one of them was defined by Conrad Waddington in 1939 
as regulation of gene expression in a heritable manner that does not involve any 
modifications [63]. Since this time more meanings have been generated for different fields 
of science, however most of the definitions are connected to molecular biology and are 
similar to the definition of epigenetics as “the study of changes in gene expression that are 
not caused by changes in the DNA sequence”. Four main mechanisms are considered as 
epigenetic processes: DNA methylation, genomic imprinting, histone modification, and non-
coding RNAs, specifically through microRNAs (miRNAs) [64]. 
MiRNAs are small, single-stranded RNA molecules of approximately 20-24 nucleotides in 
length, which act as translational repressors by either degrading or inhibiting translation of 
messenger RNA (mRNA) targets. Given the large number of miRNAs annotated in the human 
genome, 30%–80% of human genes are predicted to be influenced by miRNAs [65]. 
However, it is important to mention that miRNAs are not complementary to only one 
specific mRNA but regulate simultaneously more than one gene. Furthermore, different 
miRNAs can target the same mRNA and have similar biological functions [66]. They can 
control numerous cellular processes including metabolism, cell proliferation, apoptosis and 
differentiation in almost all cells and they are involved in processes associated with 
establishment and maintenance of pregnancy including preparation of the endometrium for 
implantation, control of genes associated with inflammatory responses and regulation of 
immune tolerance-associated genes, such as human leukocyte antigen G (HLA-G) [67, 68].  
MiRNAs seem to have an important regulatory function in eutherian organisms and some of 
them have been classified as human-specific microRNAs. The search for orthologs of 1733 
annotated human mature miRNAs across 11 species by BLAST revealed 10 miRNAs which are 
human-specific and 12 further miRNAs with human-specific seed sequences [67, 69].  
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1.5.1. MicroRNA biogenesis  
MiRNAs are transcribed from primary transcripts, which are then processed to mature 
miRNAs in two consecutive maturation steps. First, the pri-miRNAs are cleaved by the 
nuclear enzyme Drosha to form hairpin pre-miRNAs (70nt) and then, they are exported to 
the cytoplasm through Exportin-5. In the cytoplasm, the pri-miRNAs are cleaved by the 
enzyme Dicer to form mature miRNAs (19-24 nt). Finally, the mature miRNA is incorporated 
into a RNA-induced silencing complex (RISC), where it directly interacts with a member of 
the Argonaute 2 (Ago 2) protein family. The miRNA guides such protein complexes to 
partially complementary target sites, which are typically located in the 3’ untranslated 
region (UTR) of mRNAs leading to inhibition of gene expression. If alignment is partial 
complementary, the alignment leads to transcriptional repression of the target mRNA, while 
complete complementary, the cascade ends in cleavage of the target mRNA [66, 70] (Fig. 5). 
 
  
Figure 5. MicroRNA biogenesis. Inside the nucleus, pri-miRNAs are cleaved by Drosha to pre-
miRNAs and transported into the cytoplasm by Exportin 5 (green arrows). The subsequent 
cascade is shared with exogenous siRNA (red arrows). Processing by Dicer results in mature 
miRNA or functional siRNA which bind to RISC and to complementary RNA sequences. Two 
major enzymes involved in the RISC complex are Ago2 and DP130. Complete complementary 
induces degradation and partial annealing leads to translational repression (Taken from [66]). 
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MiRNA activity and abundance is regulated on various levels ranging from transcription and 
processing to target site binding and miRNA stability [70]. For instance, miRNA biogenesis is 
regulated at several steps. First by Dicer processing and Ago2 protein complex formation, 
then in unwinding of the miRNAs within the RISC, loop size-dependent recognition and 
processing by Dicer, sequence complementarity between the miRNA and the target mRNA at 
the seed region (nucleotides 2-8 of the miRNA), duplex stability in regions outside the seed 
region, and finally, the presence of DNA Alu elements in the vicinity [71]. Additionally, each 
step is also regulated by common or cell-specific signaling, such as epidermal growth factor 
receptor (EGFR) signaling. EGFR phosphorylation of Ago2, which is enhanced by hypoxia, 
attenuates its interaction with Dicer, thereby reducing miRNA processing to mature miRNAs 
[72].  
 
1.5.2.  Placental miRNA  
Placenta miRNA profiles have been studied in tissues, cell lines and maternal plasma. Most 
placenta specific miRNAs are localized within three miRNA clusters: chromosome 14 miRNA 
cluster (C14MC), chromosome 19 miRNA cluster (C19MC) and the miR-371-3 cluster (Fig. 6).  
 
 
Figure 6. Orthologs of precursor miRNAs of pregnancy related clusters: (C14MC) is uniquely 
present in eutherian species (red circle), chromosome 19 miRNA cluster (C19MC) and the miR-
371-3 cluster are just expressed in primates and conserved in humans (purple circle) (Modified 
after [67]). 
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However, some miRNAs are not present in those clusters but relevant during pregnancy. 
One of them is miR-141, a representative of the miR-200 family (Fig. 7B) that has been 
associated with nasopharyngeal and ovarian carcinomas [73]. This miRNA has been detected 
in maternal plasma and is considered as a potential pregnancy biomarker [74]. MiR-141 
might be useful for monitoring regular pregnancy progress and evaluating the status of the 
placenta [75]. However, the exact role of miR-141 has not been analyzed so far. 
 
  
Figure 7. Schematic representation and genomic organization of chromosome 14 and 12, 
containing miRNAs (Modified after [68]). 
 
Expression of miRNAs from the mentioned clusters changes during pregnancy and their 
expression differ among placentas from patients with disorders, such as PE, compared to 
normal pregnancies. Thus, they represent potential biomarkers for the respective 
pathologies. Remarkably, importance of these clusters in pregnancy might be due to their 
localization within imprinted genes involved in human embryonic development and playing 
important roles in the regulation of cellular differentiation and fate [68]. 
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1.5.2.1. Chromosome 14 miRNA cluster (C14MC) 
The large chromosome 14 miRNA cluster (C14MC), also referred to as the Mirg cluster [76] 
or the miR-379/miR-410 cluster [77] is located at the imprinted DLK-DIO3 domain on the 
human 14q32 chromosomal interval [77-79]. C14MC comprises 54 miRNAs only expressed 
from the maternally inherited chromosome, mostly in brain and placental or embryonic 
tissues [80, 81] and is uniquely present in eutherian species (the placental mammals) [76, 
80] (Fig. 7A). Recent studies have revealed that C14MC precursor sequence appeared 
approximately 100 million years ago from an early mammalian ancestor prior to the 
radiation of Metatheria (marsupial) or Prototheria (monotreme) [81] by tandem duplication 
of the ancient sequence [79, 81]. Moreover, this cluster has remained similar without 
significant structural changes in all eutherian species suggesting that it might coordinate 
important biological roles in this lineage, like neurogenesis, embryonic development, 
transcriptional regulation and RNA metabolism which support the idea that the evolution of 
placental mammals was facilitated with this cluster [80]. 
Numerous miRNAs have been investigated and the results suggest that their dysregulation is 
connected to different diseases including tumors. Furthermore, the fact that C14MC is 
expressed abundantly in the normal placenta suggests that its alteration may be related to 
obstetric disorders such as preeclampsia. Many studies have shown evidence for 
preeclampsia-related down-regulation of miRNAs. These results may provide a basis for the 
development of clinical tools for diagnosis, treatment and prognosis of preeclampsia [67].  
MiR-134, a member of C14MC, has been studied in mouse embryonic stem cells and this 
miRNA was identified as a potential regulator of dendritic spine volume and synapse 
formation in mature hippocampal neurons in vitro [82]. Mir- 134 also promotes proliferation 
of lung cancer cells [83] and is highly expressed in head and neck squamous cell carcinoma 
[84]. In a study on miRNA expression profiles of trophoblastic cells, we found that the 
expression of miR-134 is up-regulated in HTR-8/SVneo cells compared with JEG-3 cells, 
supporting the potential importance of miR-134 in pregnancy [75]. Recently, studies on cell-
free serum and plasma samples from human volunteers using small RNA sequencing of 
cDNA libraries showed that miR-134 is specifically associated with pregnancy [85]. However, 
the specific functions of miR-134 in human pregnancy still remain unclear.  
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1.5.2.2. Chromosome 19 miRNA cluster (C19MC) and miR-371-3 cluster 
Both of these clusters are encoded on chromosome 19. C19MC consists of 46 miRNA genes 
and is exclusively expressed in primates and conserved in humans, while orthologs of miR-
371-3 cluster also can be found in other eutherian mammals including mouse. C19MC 
originated from a common ancestor, which might be a member of the miR-371-3 cluster 
[68].  
The C19MC and miR-371-3 cluster are predominantly expressed in the reproductive system, 
placental tissues and in stem cells [67]. Several groups have shown that these microRNAs are 
comparatively less intensively expressed in first trimester of pregnancy, but highly expressed 
in third trimester trophoblasts and in choriocarcinoma cell lines (JEG-3, ACH-3P and AC1-
M59). After delivery, they are eliminated from the maternal blood. In contrast to the 
expression of C19MC, C14MC members decrease during the course of pregnancy [67, 71].  
 
1.6. Cell-derived vesicles: Microparticles and Exosomes 
In recent years, circulating extracellular miRNAs have attracted attention. Some miRNAs are 
stably detectable outside of cells in plasma and other body fluids of humans and these 
molecules appear to mediate cell–cell communication [86-89]. Additionally, secreted 
miRNAs are relatively well protected from digestion by RNase, conferring stability on the 
circulating miRNAs [90, 91]. Several studies have shown that extracellular miRNAs can be 
actively secreted into cell-derived vesicles such as microvesicles or exosomes for 
communication with adjacent or far distant cells [89]. The secreted miRNAs packaged in 
extracellular vesicles (EMVs) can be delivered into recipient cells and act as physiologically 
functional molecules to exert gene silencing through a similar mechanism as endogenous 
miRNAs [92]. Based on these observations it may be suggested that the intercellular transfer 
of extracellular vesicles represents a third mechanism for intercellular communication, 
different to direct cell-cell contact or transfer of secreted molecules [93]. 
The origin and nomenclature of extracellular vesicles has spread through the literature and 
different forms for called have been used [93]. EMVs are often divided into apoptotic debris, 
microvesicles (MVs)/microparticles (MPs) and exosomes (EXOs) (Fig. 8). Microvesicles are 
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phospholipid vesicles with a diameter of 100 to 1000 nm that are released by budding of the 
plasma membrane (ectocytosis) upon cell activation or apoptosis. Exosomes are preformed 
vesicles of endocytic origin with a diameter of less than 100 nm that are stored 
intracellularly in multivesicular bodies and are actively released by exocytosis from their 
paternal cells when these endosomal compartments fuse with the cell plasma membrane.  
 
  
Figure 8. Characterization of extracellular vesicles (EMVs). While exosomes share size 
distribution with viruses, microparticles overlap in size with bacteria and protein aggregates 
(e.g., immune complexes). Both, apoptotic bodies and platelets fall into the size range of 1–5 
μm (Modified after [94, 95]). 
 
Additionally to their size and origin, EMVs differ with regard to their membrane proteins and 
mode of release [94]. Despite the continuous effort to characterize and isolate EMVs, 
differences in properties such as size, morphology, buoyant density and protein composition 
seem to be insufficient for a clear distinction [93, 96]. Typical methods to separate EMVs are 
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ultracentrifugation, density-gradient centrifugation, gel chromatography or fluid-based field 
flow fractionation, with purity verified by nanoparticle tracking analysis (NTA) [97]. However, 
those methods have substantial limitations for discriminate between EXOs and MVs, 
suggesting that only when we are able to interfere with the molecular machineries required 
for EMV formation and cargo will be perfectly determined [93]. 
When the EMVs reach recipient cells, their molecular cargo may alter their phenotype and 
behavior. However, due to the different biogenesis between EXOs and MVs, they may use 
different ways to load regulatory RNAs. Some authors assume that exosomes are beneficial 
to normal pregnancy whereas microparticles may be harmful [98]. 
Functions of EMVs in physiological and pathological processes depend on the ability of EMVs 
to interact with recipient cells to deliver their contents. Target cell specificity for binding of 
EMVs is likely to be determined by adhesion molecules, such as integrins, that are present in 
EMVs. After binding to recipient cells, EMVs may remain stably associated with the plasma 
membrane or dissociate, directly fuse with the plasma membrane, or be internalized 
through distinct endocytic pathways. Endocytosed vesicles may then fuse with the delimiting 
membrane of an endocytic compartment or be targeted to lysosomes for degradation (Fig. 
9). Both forms, fusion or endocytosis, result in the delivery of protein and RNA into the 
membrane or cytosol of the target cell, potentially resulting in cell activation, phenotypic 
modification and reprogramming of cell function [93, 94]. 
Several studies have reported the presence of EMVs from human placenta [98]. Exosomes 
appear to be released mainly during the first trimester of pregnancy whereas MVs can be 
recovered from the second trimester and their concentration increases as pregnancy 
progresses [99]. This difference in the time-dependent occurrence might reflect different 
biological functions in the placenta. Exosomes contain the immunosuppressive molecules 
HLA-G involved in the immune tolerance toward the fetus whereas MVs can contribute to 
the pro-inflammatory state required for normal pregnancy. Changes in the balance between 
these EMVs may therefore be critical for the development of the maternal syndrome [98, 
99]. Therefore, circulating extracellular miRNAs may be potential noninvasive biomarkers for 
diagnosis, prevention or treatment of cancer and different pregnancy-related diseases as 
preeclampsia [100, 101]. 
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Figure 9. Intercellular communication via extracellular vesicles. EMVs are intercellular 
communicasomes harboring diverse bioactive materials including RNAs, DNAs, proteins, and 
lipids. EMVs regulate diverse range of pathophysiological functions by activating receptors of 
transferring membrane proteins, signaling molecules, mRNAs, and miRNAs. These EMVs can 
interact with the recipient cells by ligand-receptor interaction, fusion, and internalization via 
receptor-mediated endocytosis or macropinocytosis. EMVs secreted from the placenta can 
participate in an adaptive response of the mother and fetus and so interact with target tissue 
and modulate different biological processes, such as immune response, cellular adhesion, 
development and metabolism. (Modified after [102]). 
 
1.7. Pregnancy-related disease: Preeclampsia 
Various investigations have demonstrated relevance of miRNAs expression profiles in 
clinicopathological phenotypes and their possible potential as biomarkers in diverse human 
disorders, such as cancer, cardiovascular diseases, neurological disorders, viral infections 
[103] and pregnancy pathologies associated with placenta and fetal complications [104]. 
It is already known that shallow trophoblast invasion and incomplete endovascular 
transformation are leading causes of pregnancy disorders including preeclampsia, 
gestational diabetes (GDM), intrauterine growth restriction (IUGR) and low birth weight 
(LBW) [67] .  
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Preeclampsia (PE) is one common multi-system obstetric disorder naturally occurring only in 
primates and humans [105]. Around 2% to 8% of all pregnancies are affected by this 
syndrome and it has been catalogued as one of the 3 leading causes of maternal and 
perinatal morbidity and mortality worldwide [106-108]. Additionally, up to 2% of women 
with PE will progress to eclampsia leading to convulsions and potential maternal and fetal 
death [109]. Preeclampsia is characterized by hypertension (≥140/90 mmHg on two 
occasions) and proteinuria (≥300 mg protein/day) after 20 weeks of gestation [110]. 
Depending on the week of pregnancy at which the PE occurs, it can be subdivided into mild 
(also denoted early) and severe (also denoted late), initiating before 34 and after 34 weeks 
of pregnancy, respectively [109]. 
This systematic disorder may also affect the liver and the brain in the mother [111] and is 
often associated to diverse pathological processes as endothelial dysfunction, impaired 
implantation, increased intravascular coagulation, microcirculation, fibrin deposition and 
systematic inflammation in the mother [106, 109, 110]. PE is often related to complications 
in the developing fetus including prematurity, oligohydramnios, bronchopulmonary 
dysplasia, intrauterine growth restriction (IUGR), which is also characterized by trophoblast 
hypoxia and defective placental development or function, and increasing risk of perinatal 
death [111, 112]. 
As mentioned above, during normal placentation, the embryo-derived cytotrophoblast cells 
invade the maternal uterine wall and induce the remodeling of maternal vessels into high 
capacitance, low resistance vessels which provide access to maternal oxygen and nutrients 
for the placenta and developing fetus [113]. As a result of this process, the cytotrophoblasts 
adopt an endothelial phenotype, expressing adhesion molecules classically found on the 
surface of endothelial cells. In PE this process is restricted, characterized by shallow 
cytotrophoblast invasion only in the superficial layers of the decidua without adopting an 
endothelial adhesion phenotype. Finally, the spiral arteries fail to be remodeled, resulting in 
constricted, high resistance vessels (Fig. 10) [111].  
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Figure 10. Abnormal Placentation in Preeclampsia. In normal placental development, invasive 
cytotrophoblasts of fetal origin invade the maternal spiral arteries, transforming them from 
small-caliber resistance vessels to high-caliber capacitance vessels capable of providing 
placental perfusion adequate to sustain the growing fetus. During the process of vascular 
invasion, the cytotrophoblasts differentiate from an epithelial phenotype to an endothelial 
phenotype, a process referred to as “pseudovasculogenesis” or “vascular mimicry” (Upper 
Panel). In preeclampsia, cytotrophoblasts fail to adopt an invasive endothelial phenotype. 
Instead, invasion of the spiral arteries is shallow and they remain small caliber, resistance 
vessels (Lower Panel) (Taken from [111]). 
 
Since the past decade, the pathogenesis of preeclampsia has been a frequent topic of 
studies investigating the heterogeneous nature of this syndrome but its etiology remains 
unknown [110]. Several hypotheses have been postulated in an attempt to explain its 
pathogenesis. Some of them suggest that PE can be a result of failure in villous trophoblast 
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differentiation early in pregnancy, which leads to necrosis and apoptosis of trophoblast cells 
and increased release of fragments into the maternal circulation, such as EMVs [109].  
Due to the incomplete knowledge on PE, effective preventions or treatments still have to be 
discovered. The most common solution is to deliver the baby and the placenta, often 
prematurely, in the interest of providing the most appropriate conditions for the newborns 
or their mothers [114]. Currently, it is assumed that a better understanding of the role of 
EMVs containing miRNA in PE can contribute to a better comprehension of this 
etiopathogenesis and promising clinical approaches [109].  
Recent studies have shown a large number of miRNAs with potential importance in PE [67, 
68, 115]. Several, indicated a relation between miRNAs and exosomes or MVs and its 
different roles in normal pregnancies and in PE. However, more research for tracking the 
trafficking of EMVs and miRNA cargo is required. The elucidation of this topic will be 
important for optimization of tools for therapeutic targeting of miRNAs in this and other 
disorders. 
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Chapter 2/Aims  
 
2.1. General objectives 
To elucidate molecular mechanisms associated with EGF signaling and miRNA gene 
regulation which may be responsible for the control of trophoblast proliferation and invasion 
in normal and preeclamptic pregnancies.  
To contribute to the identification of novel miRNAs as potential diagnostic tools for 
therapeutic targeting of pregnancy disorders. 
 
2.2. Specific objectives:  
To investigate the function of EGF on trophoblast cell proliferation and invasion through 
activation of STAT5.  
To analyze the role of miR-141 and miR-134 in the regulation of central functions of 
trophoblast cells: proliferation and invasion. 
To compare the expression of miR-141 in normal and preeclamptic placentas and to 
investigate its role in the intercellular communication mediated by microvesicles.  
 
This study will be subdivided in three parts: 
 Analysis of EGF functions in trophoblast models (Fig. 11A). 
 Investigation of effects of miR-141 and miR-134 on the regulation of trophoblast cell 
lines (Fig. 11B). 
 Analysis of miR-141 expression in normal and preeclamptic placentas and of its role 
in the intracellular communication mediated by microvesicles (Fig. 11C). 
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Figure 11. Experimental design of this work. A. Function of EGF in trophoblastic cells through 
regulation of STAT5 activation. B. MiRNAs expression in trophoblastic cell lines. C. MiR-141 
expression in normal and preeclamptic placentas. 
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Chapter 3 / Materials and Methods 
 
3.1.  Human cell lines and cell culture 
The trophoblastic cell lines JEG-3 and JAR were commercially obtained from ATCC (USA, Cat-
No. HTB-36 or HTB-144). HTR-8/SVneo was obtained as a kind gift from Professor Charles 
Graham of the Department of Anatomy and Cell Biology at Queen's University, Kingston, ON, 
Canada. All cultures were commenced at 106 cells/175 cm2 flask and cultured in F12 or 
RPMI-1640 medium (PAA Laboratories GmbH, Cölbe, Germany) supplemented with 10% 
fetal bovine serum (FBS), and 1% of penicillin and streptomycin (PAA Laboratories GmbH) 
under standard conditions of 5% CO2 at 37°C and medium renewal every 2 days. 
Consequently, Jurkat, a human T cell line, (DSMZ, Braunschweig, Germany) was cultured in 
RMPI-1640 medium (PAA Laboratories GmbH, Cölbe, Germany) under the same conditions 
as applied for the trophoblastic cell lines. The cells were trypsinized regularly and adjusted to 
105 cells/ml. The cell lines were inspected for absence of mycoplasma on a routine basis. 
Extravillous trophoblast cells were isolated from term placenta tissue using a modified 
Kliman method as described in detail by Stenqvist [116] and standardized in Placenta Labor. 
Placental tissue was physically disaggregated and enzymatically digested for 30 min. After 
washing, isolated cells were applied on a density gradient (Percoll, Pharmacia, Sweden) and 
the fraction retained within the layer of 25% Percoll was collected and washed. For 
depletion of non-trophoblastic cells, Dynabeads coated with anti-CD45 and anti-CD82 
antibodies (Life Technologies, Darmstadt, Germany) were used. Before use for RNA isolation, 
isolated cells were cultured for two days in F-12 medium (PAA) supplemented with 10% FCS. 
Adherent cells were checked for purity by flow cytometry using anti-EGF-receptor, anti-
cytokeratin-7, and anti-HLA-G antibodies. 
 
3.1.1. JAR and JEG-3 cell lines  
The JAR cell line has been established by R. A. Pattillo and derives directly from a placental 
trophoblastic tumor of a 24-years-old caucasian woman (Patillo and Grey 1968). The JEG-3 
cell line was established by Kohler in the early 1970’s from a human gestational 
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choriocarcinoma that was taken at an autopsy from a cerebral metastasis (Kohler and 
Bridson 1971) (Fig. 12). 
JAR and JEG-3 cells grow in vitro as monolayers and exhibit epithelial morphology [117]. 
Some dissimilarities between JEG-3 cells and villous trophoblast phenotypes have been 
reported, including polyploidy and expression of membrane bound HLA-E and HLA-C and 
soluble HLA-G1 by JEG-3 cells [118]. Despite them, JEG-3 cells are widely used as model for 
trophoblast behavior and several studies in JAR and JEG-3 cells could be extrapolated to 
trophoblast in vivo.  
 
3.1.2. HTR-8/SVneo cell line 
The immortalized human first-trimester trophoblast cell line HTR-8/SV40 was established in 
1993 by Lala PK and associated. They introduced the gene encoding simian virus 40 large T 
antigens into first trimester human extravillous trophoblast cells. The resulting cell line 
shares several phenotypic properties with the parental trophoblasts but with an extension of 
the lifespan [119] (Fig. 12). 
 
3.1.3. Jurkat cell line 
The Jurkat cell line is an immortalized line of human T lymphocyte cells obtained for 
screening purposes from John Hansen at the Fred Hutchinson Cancer Research Center, 
Seattle, USA. However, during its standardization, the cells were heavily contaminated with 
mycoplasma. The process of curing the cell line of this infection yielded the Jurkat E6-1 
clone, which eventually became the standard Jurkat cell line used by many T cell   
immunologists. This human T cell line spontaneously or inducibly releases large quantities of 
IL-2 after stimulation with phytohaemagglutinin (PHA) [120] (Fig. 12). 
 
 
 
 25 
JEG-3 JAR
HTR-8/SVneo JURKAT
 
Figure 12. Human cell lines used for this thesis. The trophoblastic cell lines JEG-3 and JAR, the 
immortalized human trophoblast cell line HTR-8/SVneo (adherent cell lines) and human T 
lymphocyte cell line Jurkat (suspension cell line). 
 
3.2. Cell Stimulation 
All cell lines were treated with cytokines and growth factors at various concentrations. EGF 
(100 ng/ml) and LIF (10 ng/ml) were purchased from Millipore (Bellerica, MA, USA). GM-CSF 
(20 ng/ml); IL-11 (20 ng/ml) and IL-2 (20 ng/ml) were purchased from Immunotools 
(Friesoythe, Germany). 
 
3.3. STAT5 mRNA expression in trophoblastic cells 
Extravillous trophoblast cells were isolated from term placenta tissue and cultured for two 
days before of RNA isolation. Briefly, JAR and HTR-8/SVneo cells were seeded in 6-well plates 
and serum deprived for 2 h before total RNA extraction with Trizol reagent (Invitrogen, 
Darmstadt, Germany). Total RNA concentration and quality were determined at a NanoDrop 
 26 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). Samples with 
A260/A280 ratio greater than 1.8 were stored at −80°C until being processed. 
50 ng of total RNA were reverse-transcribed using High capacity RNA-to-cDNA kit (Applied 
Biosystems Darmstadt, Germany). Real-time qPCR was performed using TaqMan gene 
expression assays with specific primers for STAT5B (Assay ID Hs00560035_m1), GAPDH 
(Hs03929097_g1) (Applied Biosystem, Darmstadt, Germany). Reactions were run in 
duplicates, including no-template controls in 96-well plates on an Mx3005P QPCR System 
(Applied Biosystems). Relative STAT5B mRNA expression was quantified by using the 2-DCt 
method relative to GAPDH.  
 
3.4. Western blot assay 
Cells were seeded in 6-well plates at a density of 1 × 105 cells and allowed to attach 
overnight. The next morning, cells were serum starved for 2 h before stimulation with EGF 
(100 ng/ml), GM-CSF (20 ng/ml), LIF (10 ng/ml), IL-11 (20 ng/ml) and IL-2 (20 ng/ml) for 15 
min. After treatment, cells were washed with PBS and protein lysates were subjected in lysis 
buffer to three freeze/thaw cycles. Cell lysates were cleared from particles by centrifugation 
at 18,000 rpm for 30 min at 4°C. Protein concentration was measured using Bradford dye 
and a microplate reader according to the manufacturer´s protocol (Bio-Rad, Hercules, Calif, 
USA). For each sample, 20 µg of protein was re-suspended in 4% stacking gel (30% AB; 0.5 M 
SGP; 20% SDS; ddH2O; 20% APS and TEMED) and separated by 7.5% running gel (30% AB; 1.5 
M TGP; 20% SDS; ddH2O; 20% APS and TEMED). Proteins were transferred to a PVDF 
membrane by electrophoretic transfer (Thermo Scientific, Rockford, IL, USA). Membranes 
were blocked with TBS-T (Tris-buffered saline containing Tween-20) containing 5% milk, 
blotted with rabbit primary antibody (1:1000) against phospho(p)-STAT5(tyr694), STAT5, p-
STAT3(tyr705), STAT3, p-ERK1/2(thr202/tyr204), ERK1/2 or alpha-tubulin (all Cell Signaling, 
USA), overnight at 4°C. Blots were washed 3 times in TBS-T, incubated for 60 min with anti-
rabbit IgG, HRP-linked antibody (Cell Signaling, USA), and washed with TBS-T. A 
chemiluminescent detection system (LuminataTM Forte, Millipore, US) was used and 
chemiluminescense of bands was analyzed on a ChemiBIS bio-imaging system (Biostep 
GmbH, Jahnsdorf, Germany).  
 27 
3.5. STAT5 siRNA transfection 
JAR and HTR-8/SVneo cells were seeded in 6-well plates at a density of 3 × 105 cells/well. 
After 12 h, cells were washed with OPTIMEM (GIBCO) and resuspended in 800 µl fresh 
OPTIMEM. Thereafter, cells were transfected with predesigned small interfering RNA (siRNA) 
for STAT5B or the control (Ambion). The following 5`-3` oligonucleotide sequence has been 
used: Sense: GCAUACACCAUUGCUUGGAAtt. The non-genomic control sequence was: 
GCCACUUAUAAAUUCGUUCtt. The transfection was performed with Oligofectamine 
Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer´s 
recommendations. Concentrations of oligonucleotides and Oligofectamine dilution were 66 
nM and 1:2.75, respectively. After 4 h of treatment, transfections were stopped by addition 
of DMEM medium (Life technologies) containing 30% FBS. Cells were incubated at 37°C 
overnight before seeding for viability, proliferation and invasion assays.  
 
3.6. Immunocytochemistry 
JAR and HTR-8/SVneo cells were seeded at a density of 1.5 × 104 cells on Microscope Slides 
(Thermo Scientific™), allowing them to attach overnight, and then stimulated or not with 
EGF (100 ng/ml) for 15 min. Staining of cells was performed by using a Vectastain Elite ABC 
Kit (Vector Laboratories, Burlingame, USA) as follows: cells were fixed in ethanol/methanol 
1:1 for 5 min, washed in 0.1 M PBS and nonspecific antigens were blocked with normal goat 
serum for 20 min at RT. After blocking, slides were incubated 1 h with the primary antibody 
diluted 1:100 (anti-p-STAT5) (Cell Signaling) or Rabbit (DA1E) mAb IgG Isotype Control (Cell 
Signaling) in Antibody Diluent (DAKO, Hamburg, Germany), rinsed thrice and incubated 30 
min with biotinylated affinity-purified anti-rabbit-IgG (Cell Signaling). Thereafter, slides were 
treated with a solution of Avidin/Biotinylated enzyme Complex (ABC; Thermo Fisher 
Scientific, Bonn, Germany) for 30 min, followed by 2 min staining with NovaRed-Kit (Vector 
Laboratories; Burlingame, CA, USA), and counterstained with hematoxylin for 2 min. Finally, 
slides were dehydrated by an ethanol-to-xylene treatment and covered with Histofluid (Paul 
Marienfeld, Lauda-Königshofen, Germany). Staining images were visualized on a Zeiss 
Axioplan 2 microscope (Carl Zeiss, Jena, Germany). 
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3.7. DNA-Binding capability assay 
Cells were cultured in 6-well plates at a density of 1 × 105 cells and stimulated with EGF (100 
ng/ml) for 30 min. Nuclear and cytoplasmic protein extraction was performed using a 
Nuclear Extract Kit (Active Motif, Belgium) according to the manufacturer’s instructions. 
Protein concentrations were assessed by a Bradford assay (Bio-Rad, Hercules, CA, USA). 
DNA-binding detection was performed by using a Transcription Factor Assay Kit (Active 
Motif, Belgium). Briefly, nuclear proteins were incubated on an oligonucleotide coated plate 
and incubated with a 1:1000 dilution of anti-STAT5 antibody in 1x antibody binding buffer 
for 1 h. The secondary HRP-conjugated antibody (1:1000) was applied for 1 h. Nb2 (prolactin 
stimulated) was used as a positive control. Developing solution was added for 10 min at RT 
followed by addition of stop solution. Absorbance was read in a SPECTROstar Omega (BMG 
Labtech, Offenburg, Germany) at 450 nm with a reference wavelength of 655 nm.  
 
3.8. Functional Assays 
 
3.8.1. Cell Viability  
JAR and HTR-8/SVneo cells (10000 cells/well) were seeded in 96-well plates, allowing them 
to attach overnight and then serum starved for 2 h before stimulation with 100 ng/ml EGF. 
Cell viability was analyzed with a tetrazolium salt (MTS) assay (CellTiter96™, Promega, USA) 
after 0 (non-stimulated), 24 and 48 h stimulation. Briefly, new RPMI medium containing MTS 
(1:6 dilution) was added to the cells and color development was measured as optical density 
(OD) at 490 nm on a ELISA plate reader (SPECTROstar Omega; BMG Labtech, Offenburg, 
Germany). The color reaction of this assay is dependent on tetrazolium dye reduction 
through NAD(P)H-dependent oxidoreductase enzymes which correlates with the cellular 
metabolic activity. Cell viability at all time points was expressed as blank-corrected OD 
normalized to that of non-treated cells at 0 h.  
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3.8.2. Proliferation assay 
JAR and HTR-8/SVneo cells (10000 cells/well) were seeded in 96-well plates, allowed to 
attach overnight and then serum starved for 2 h before stimulation with 100 ng/ml EGF. Cell 
proliferation was assessed by “Cell proliferation ELISA, BrdU” assay (Roche, Germany) at 0 
(non-stimulated), 24 and 48 h stimulation. After treatment, cells were incubated 2 h with 
new RPMI containing BrdU labeling solution (1:1000). After removing the medium, cells 
were fixed and the DNA was denatured by treatment with FixDenat. Then, wells were 
incubated 90 min with peroxidase labelled anti-BrdU-Fab fragments. After rinsing, the 
immune complexes were detected by incubation with tetramethyl-benzidine (TMB). After 30 
min, color development was measured at 370 and 492 nm on an ELISA plate reader 
(SPECTROstar Omega; BMG Labtech, Offenburg, Germany). Corrected absorbance values 
(A370-A492) correlate with the amount of DNA synthesis and thus, with the number of 
proliferating cells. Cell proliferation at all-time points was expressed as corrected 
absorbance and normalized to that of non-treated cells at 0 h.  
 
3.8.3.  Cell Invasion assay 
Invasion assays were performed in 24-well plates by using transwell inserts of 8 µm pore size 
(BD Biosciences) coated with 1:3 diluted Matrigel (BD Biosciences). 1 x 105 cells per well 
were placed on the upper side of the inserts in 200 µl of medium containing or not EGF (100 
ng/ml). After 24 h, cells in the lower side of the inserts were fixed in cold ethanol and stained 
with 0.1 % crystal violet. Formed color crystals were resolved in acetic acid and solutions 
were transferred into 96-well plates. Absorbance was measured at 570 nm in a SPECTROstar 
Omega plate reader (BMG Labtech). Cell invasion was expressed as absorbance of treated 
cells normalized to that of controls. 
 
3.9. Patient samples  
Patients aged between 18 – 32 years were recruited for the analysis from the University 
Hospital Jena, Germany. Five patients with confirmed diagnosis of preeclampsia and five 
age-matched controls were included. Tissues of the placental villi were collected 
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immediately after delivery under visual observation and washed with physiological serum to 
remove excess blood cells. Samples were placed into cryotubes, covered completely with 
RNA later (Ambion, Austin, TX, USA) and stored at -80°C until RNA extraction. All samples 
were collected with the informed consent of the patients. The project was approved by the 
Ethics Committee of University Hospital Jena.  
 
3.10. RNA Isolation and Quantitative Real-time PCR 
JEG3 and HTR-8/SVneo cells were seeded in 6-well plates and serum deprived for 2 h and 
total RNA was extracted from cells using Trizol reagent as per the manufacturer´s 
instructions (Invitrogen, Darmstadt, Germany). Total RNA concentration was determined 
with a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). 
Samples with A260/A280 ratio greater than 1.8 were stored at −80°C until being processed. 
Blocks of 1 cm diameter of each placenta were cut with a mean weight of ~ 100 mg. 
Thereafter, one of the samples was transferred to a disposable for biological sample 
disaggregation (Medicons) for use on a Medimachine according to the manufacturer's 
protocol (C.T.S.V., Brescia, Italy). The cellular suspension was collected and subsequently, 
total RNA was isolated by using a mirVana isolation kit (Life Technologies), according to the 
manufacturer's protocol. 
Thereafter, 100 ng or 10 ng of total RNA, obtained from cell lines or tissues samples, 
respectively, were reverse-transcribed, and real-time PCR was performed using TaqMan 
miRNA assays with specific primers for hsa-miR-141 (UAACACUGUCUGGUAAAGAUGG), and 
the endogenous control, RNU48 (GATGACCCCAGGTAACTCTGAGTGTGTCGCTGA 
TGCCATCACCGCAGCGCTCTGACC), (Applied Biosystem, Darmstadt, Germany). All reactions 
were run in duplicates, including no-template controls in 96-well plates on an Mx3005P 
QPCR System (Applied Biosystems). The experiments from cell lines were repeated three 
times and Student´s t-test was performed (p< 0.05).  
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3.11. Transfection with miR-141 mimic and antagomir  
Cells were seeded in 6-well plates allowed to attach overnight to reach 30-50% confluence at 
the time of transfection. Expression of miR-141 was analyzed with either MiRIDIAN 
microRNA Mimic (Pre-miR-141) or Hairpin inhibitor (Anti-miR-141) specifically designed for 
these miRNAs or the respective non-genomic negative controls (Thermo Fisher Scientific, 
Schwerte, Germany). These miRNA were transfected into both trophoblastic cell lines at a 
final concentration of 25 nM by using Oligofectamine reagent (Invitrogen life technologies, 
Darmstadt, Germany) according to the manufacturer´s recommendations. After 24 hours of 
transfection, cells were trypsinized and seeded into plates for viability, proliferation and 
invasion assay. Expression level of miR-141 was analyzed by real time qPCR. Transfection 
indicator (siGLO Green, Thermo Fisher Scientific, Schwerte, Germany) was used for 
monitoring transfection efficiency. 
 
3.12. Isolation of microparticles or exosomes from cell lines’ supernatants  
After transfection with miR-141 mimic (Pre-miR-141) or the respective control, five ml of 
new medium supplemented with 10% FBS was added to the cells. After 2 days of culture, the 
supernatants of each treatment with MiRIDIAN were collected and transferred into new 
tubes. Thereafter, the samples were stored at -80°C until microparticles (MPs) or exosomes 
(EXOs) were extracted. After thawing of supernatants, the suspension was centrifuged twice 
at different speed in order to remove dead cells and cell debris. The obtained supernatants 
were centrifuged for 30 min at 18.890xg at 4°C and pellets containing the microparticles 
were separated from the supernatant. The supernatants were transferred into centrifuge 
tubes (Beckman Coulter) and the pellets (microparticles) were resuspended in 5 ml PBS and 
again centrifuged for 30 min at 18.890xg at 4°C for discarding contaminating proteins. The so 
generated pellets contained exclusively microparticles at reduced concentrations of free 
proteins. The supernatants were filtrated using filters with 0.8/0.2 µm pore size (Pall Life 
Sciences) and centrifuged at 100.000xg for 70 min at 4°C. Finally, the pellets were suspended 
in 5 ml PBS and a new centrifuged at 100.000xg for 70 min to obtain pellets containing 
exosomes. Total RNA was extracted from both pellets (microparticles and exosomes) by 
using Trizol reagent as per the manufacturer´s instructions (Invitrogen) and 10 ng of total 
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RNA, was reverse-transcribed, and real-time PCR was performed using TaqMan miRNA 
assays with specific primers for hsa-miR-141 as mentioned before. Microparticles and 
exosomes pellets were re-suspended in 1 ml PBS and stored at -80°C until being used in 
functional assays (Fig. 13).   
 
 
Figure 13. Experimental design for the isolation of microparticles (MPs) and exosomes (EXOs) 
from cell culture supernatants after over-expression of miR-141. 
 
3.13. Nanoparticle Tracking Analysis 
Nanoparticle tracking analysis (NTA) was performed using NanoSight Version 2.3 Build 0033 
instrument (NanoSight Ltd., Amesbury, UK) following the manufacturer´s instructions. This 
instrument passes a focused 488 nm laser beam through a suspension of the sample of 
nanoparticles and collects the scattered light using conventional microscope optic aligned at 
90° to the beam axis. Then, an electron multiplying charge coupled device captures a video 
of the field of view at 30 frames per second. The NanoSight instrument measures the rate of 
Brownian motion of each nanoparticle from frame to frame, thus enabling the calculation of 
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the hydrodynamic diameter via the Stokes-Einstein equation. Finally, the system provides a 
reproducible platform for specific and general nanoparticle characterization. Samples of MPs 
and EXOs were diluted in PBS over a range of concentrations to obtain between 10 and 100 
particles per image prior to analysis with NTA system. Then, the respective solutions were 
introduced into the sample chamber and ten 20-second videos were recorded (shutter 
speed of 600; camera gain of 250). The captured videos were then processed and analyzed 
using optimized instrument settings (detection threshold 7 Multi; blur automatic; and Min 
Expected Size automatic) and an Excel spreadsheet (Microsoft Corp., Redmond, Washington) 
was automatically generated, showing mean, mode, and median particles size together with 
an estimate of the number of particles. 
 
3.14. Statistics 
All experiments were repeated at least three times. Statistical significance was performed 
using a two-tailed Student´s t-test. p< 0.05 was recognized as statistically significant.  
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Chapter 4/ Results 
 
4.1. Function of EGF in trophoblastic cells through regulation of STAT5 activation.  
First trimester extravillous cytotrophoblast (EVT) invasion plays an important role for 
placental growth and success of pregnancy. The process of placentation is regulated by 
cytokines and growth factors signaling via the JAK/STAT pathway. One of which is EGF. 
Extravillous trophoblast cells were isolated from placenta tissue. STAT5B mRNA expression 
was similar in isolated trophoblast cells and HTR-8/SVneo cells but significantly lower in JAR 
cells when compared with primary cells (1.03-fold) (Fig. 14).  
 
 
Figure 14. Basal STAT5B mRNA expression in isolated trophoblast cells and the cellular models 
HTR-8/SVneo and JAR cells. STAT5B mRNA levels are calculated as fold change (2-ΔΔCt) with 
GAPDH as endogenous control and normalized to primary trophoblast cells (Troph). *** p< 
0.005 (Student’s t-test). 
 
4.1.1. EGF induces STAT5 activation 
Western blots demonstrate that only LIF (10 ng/ml) administration induces phosphorylation 
of p-STAT3 (tyr705) in both HTR-8/SVneo and JAR cells while p-STAT5 (tyr 694) is induced 
exclusively by EGF (100 ng/ml) (Fig. 15A). EGF-induced STAT5 phosphorylation is maximal 
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after 15 min and returns to background level after 30 min (data not shown). Basal expression 
of p-STAT5 is slightly higher in HTR-8/SVneo cells than in JAR cells as observed by Western 
blot and immunocytochemistry analysis (Fig. 15A-B). P-STAT5 was localized initially in the 
cytoplasm and after treatment with EGF, the levels in the nuclei increased (Fig. 15B). 
To confirm that EGF induces STAT5 activation and translocation into the nucleus, DNA-
binding capacity of STAT5 has been analyzed. It increases slightly, but not significantly upon 
stimulation with EGF in both cell lines (Fig. 16). 
 
Figure 15. A. Effects of EGF on phosphorylation of STAT3 and STAT5 in HTR-8/SVneo and JAR 
cells. Representative Western blots of cells stimulated 15 min with EGF (100 ng/ml). B. 
Immunocytochemical staining of p-STAT5 (tyr694) in HTR-8/SVneo and JAR cells before (left 
panels) and after incubation (right panels) with EGF (100 ng/ml). Negative controls are shown 
in the upper corner of each treatment. 
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Figure 16. Relative STAT5 DNA-binding capacity of cells treated or not with EGF (100 ng/ml) for 
30 min as assessed by a colorimetric assay. Values of controls have been defined as “1” and 
used for normalization. Bars represent mean values of n=3 independent experiments. Error 
bars indicate standard error of the mean. For positive control 5 µg lysate of the Nb2 lymphoma 
cell line has been used, which expresses constitutively phosphorylated STAT5. 
 
4.1.2. EGF stimulates cell viability and invasion in a mechanism involving STAT5B  
After 48h of treatment with EGF (100 ng/ml), viability of HTR-8/SVneo and JAR cells 
increases by 41% and 29%, respectively (p< 0.05; Fig. 17A). Cell proliferation assessed by 
BrdU incorporation was only increased in HTR-8/SVneo cells (by 14%) but not in JAR cells 
(Fig. 17B).  
 
 
Figure 17. Effect of EGF on the viability of HTR-8/SVneo and JAR cells. Cells were incubated in 
presence or absence of EGF (100 ng/ml) for 48h. Cell viability and proliferation have been 
analyzed by MTS (A and C) or BrdU (B and D) colorimetric assays, respectively, as described in 
Material and Methods. Left panels: JAR cells, right panels: HTR-8/SVneo cells. Control values 
have been defined as “1” and used for normalization. Bars show mean values of n=4 
independent experiments (each performed in triplicates) ± SEM. * p< 0.05 (Student´s t-test). 
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As confirmed by Western blotting, STAT5B was significantly down-regulated after 
transfection with STAT5B siRNA (Fig. 18). This knock-down results in a slight decrease 
of cell viability in both cell lines when compared to non-genomic transfected cells. In 
presence of EGF, cell viability of STAT5-silenced cells was significantly lower in 
comparison to that of controls (Fig. 18). Remarkably, cell viability in siSTAT5 
transfected cells was similar before and after EGF treatment. 
 
 
Figure 18. Relative viability of trophoblastic cells after STAT5B silencing and EGF stimulation. 
Cells were transfected with specific STAT5B siRNA or non-genomic siRNA and subsequently, 
incubated for up to 48 h in presence or absence of EGF (100 ng/ml). Results were normalized 
to non-stimulated cells at 0 h (non-stimulated cells, values defined as “1”) and are expressed 
as mean (n=4 independent transfections, each experiment performed in triplicates). Error bars 
indicate SEM. (NTC: non-transfected cells, SCR: cells transfected with non-genomic siRNAs, 
STAT5B: siRNA specific for STAT5B. * p< 0.05 (Student’s t-test) for the indicated comparison. 
Upper corners show representative Western blots of STAT5 expression before and after 
silencing.  
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4.1.3. EGF-enhanced HTR-8/SVneo invasion is mediated by STAT5 
The capacity of cells to invade through Matrigel has been monitored as described in 
“Material and Methods”. JAR cells show 25% higher spontaneous invasion than HTR-
8/SVneo cells. Silencing of STAT5B alone did not affect invasion capability in any cell line. 
After 24h of treatment with EGF, invasion was increased in HTR-8/SVneo cells (1.35 fold) but 
not in JAR cells. EGF-stimulated invasion of HTR-8/SVneo cells was significantly reduced after 
STAT5 silencing by 34% (Fig. 19). 
 
Figure 19. Relative invasiveness of trophoblastic cells after STAT5B silencing and EGF 
stimulation. Cells were transfected with STAT5 siRNA and seeded on transwell chambers 
coated with Matrigel in presence or absence of EGF (100 ng/ml). Relative invasion was 
measured after 24 h. Results are normalized to non-stimulated cells. Error bars indicate SEM. 
(NTC: non-transfected cells, SCR: cells transfected with scrambled, non-genomic siRNAs, 
STAT5B: siRNA specific for STAT5B. * p< 0.05 (Student’s t-test) for the indicated comparison. 
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4.2. MiRNAs expression in trophoblastic cell lines and placenta tissue 
 
4.2.1. Biological relevance of miRNAs in pregnancy 
Human placenta tissue exhibits a specific miRNA expression pattern that dynamically 
changes with the gestational age and its alteration may result in pregnancy complications 
[68]. Two reviews providing a general overview on pregnancy-specific miRNAs were written. 
The first review showed the current knowledge on the origin and expression of human 
placenta miRNAs, as well as their interspecies differences [67]. In the second review, the 
state-of-the-art about the expression of pregnancy-related miRNA clusters (C14MC, C19MC 
and miR-371-3 cluster), their correlation with pregnancy disorders and their possible 
relevance as biomarkers for the detection and treatment of pregnancy-associated diseases 
were summarized [68].  
Based on the information of the reviews and previous studies performed by our laboratory, 
the importance of expression of a larger miRNA clusters located on the chromosome 14 
(C14MC) has been emphasized. Among the members of this cluster, miR-134 was highly 
expressed in first trimester but comparatively low in third trimester trophoblast cells [75]. 
Additionally, the literature and previous studies from our group report the importance of 
some miRNAs during pregnancy which are not localized within C14MC or C19MC. One of 
them is miR-141, a representative of the miR-200 family [73]. However, the role of miRNA-
134 and miRNA-141 in trophoblast cells has not yet been investigated in detail.  
In this part of the work, the expression of miR-134 and miR-141 were analyzed in the two 
trophoblastic cell lines JEG-3 and HTR-8/SVneo and their effects on proliferation and 
invasion, after inhibition or over-expression. Simultaneously, the expression of miR-141 in 
placenta tissues was analyzed (Table 1).  
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Table 1. Clinical characteristics of patients from which placenta tissues samples have been 
used in the study 
 Normal PE p 
 Average SD Average SD  
Age, years 26.50 6.81 26.20 3.03 0.93 
Gestational age, weeks 39.68 0.84 34.89 3.11 0.02 
Birth weight, g 3520.00 140.65 2221.00 642.71 0.01 
Mode of delivery: Cesarean section % 40.00  100.00   
 
4.2.2. Effect of miR-134-mimic or –antagomir transfection on cell proliferation 
and invasion  
MiR-134 was highly expressed in HTR-8/SVneo but was lower or not expressed in JEG-3 cells 
(Fig. 20). Silencing of miR-134 in HTR-8/SVneo cells altered invasion when compared with 
non-genomic control, while overexpression did not changed (Fig. 21 A-C). Cell proliferation 
was significantly inhibited in HTR-8/SVneo cells transfected with miR-134-mimic but miR-134 
inhibition did not lead to an increase (Fig. 21 B-D). Viability did not change significantly (data 
not show). 
  
Figure 20. Basal miR-134 expression in JEG3 and HTR-8/SVneo cells. 2-ΔΔCt was used to indicate 
miRNA expression relative to RNU48 (endogenous control) and normalized to HTR-8/SVneo 
cells. Δ∆Ct =(CtmiR-134-CtRNU48)Sample- (CtmiR-134-CtRNU48)HTR-8/Svneo . Bars correspond to mean ± SD 
(n=4). 
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Figure 21. Effect of miR-134 inhibition or overexpression on invasion and proliferation of HTR-
8/SVneo. Cells were transfected with either miR-134-antagonist (Anti-miR-134) or miR-134 
mimic (Pre-miR-141) and invasion was assessed by Matrigel (A-B) or proliferation by BrdU (C-
D) assays. CTR: non-transfected cells; Anti-CTR and Pre-CTR: non-genomic sequence, 
respectively to antagonist or mimic. * p< 0.05 (Student’s t-test). 
 
4.2.3. MiR-141 is upregulated in preeclamptic pregnancies tissues. 
Expression levels of miR-141 were detected in 5 PE and 4 normal placental tissues samples 
by RT-qPCR. MiR-141 was significantly increased in PE placenta when compared with normal 
controls (1.64-fold P < 0.05). Basal levels of miR-141 were similar in JEG-3 and HTR-8/SVneo 
cells but were significantly lower than in normal tissues (Fig. 22). Transfection with miR-141-
mimic resulted ~5,600-fold and ~3,993-fold increased expression in HTR-8/SVneo and JEG-3 
cells, respectively. Conversely, treatment with miR-141-inhibitor reduced miR levels in 70% 
in HTR-8/SVneo and 60% in JEG-3 cells.  
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Figure 22. Scatter plot of miR-141 expression in placentas from preeclampsia (PE, n=5) and 
normal pregnancy (NP, n=4), or the trophoblast cell lines HTR-8/SVneo and JEG-3 (n=4). miR-
141 expression was calculated as fold change (2-ΔΔCt) with RNU48 as endogenous control and 
normalized to NP. * p< 0.05 *** p< 0.001 (Student’s t-test). 
 
4.2.4. Effect of miR-141-mimic or –antagomir transfection on cell proliferation  
Fourty-eight hours after transfection with neither miR-141-mimic nor miR-141-inhibitor No 
significant changes were observed in HTR-8/SVneo viability, measured by MTS assay, (Fig. 
23A-B). After miR-141 inhibition, viability of JEG-3 cells decreased when compared with non-
genomic control (p< 0.1; Fig. 23A) but miR-141 over-expression did not lead to an increase 
(Fig. 23B).  
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Figure 23. Effect of miR-141 inhibition or overexpression on viability and proliferation of 
trophoblastic cell lines. JEG-3 and HTR-8/SVneo cells were transfected with either miR-141-
antagonist (Anti-miR-141; upper panel) or miR-141 mimic (Pre-miR-141; lower panel) and cell 
viability was assessed by MTS (a-b) or proliferation by BrdU (c-d) assays. CTR: non-transfected 
cells; Anti-CTR and Pre-CTR: non-genomic sequence, respectively to antagonist or mimic. * p< 
0.05 (Student’s t-test). 
 
4.2.5. MiR-141 regulates cell invasion 
The capacity of cells to invade through Matrigel has been monitored 48hr after inhibition or 
overexpression of miR-141. A direct correlation between miR-141 levels and cell invasion 
was confirmed in the HTR-8/SVneo cell line but not in JEG-3 cells. Cell invasion was 
significantly inhibited in both HTR-8/SVneo and JEG-3 cells transfected with anti-miR-141 
(Fig. 24A), while it was significantly increased after transfection with miR-141 mimic only in 
HTR-8/SVneo cells (Fig. 24B). 
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Figure 24. Effect of miR-141 inhibition or overexpression on invasiveness of trophoblastic cell 
lines. Cells were transfected with A. miR-141 inhibitor (Anti-miR-141) or B. miR-141 mimic 
(Pre-miR-141) or the respective controls (Anti-CTR and Pre-CTR) and invasiveness was assessed 
by Matrigel assay after 48 h. Bars represent mean ± SE. *p<0.05 (two-tailed Student’s t test). 
          
4.3. Characterization of isolated exosomes and microparticles  
Microparticles (MPs) and exosomes (Exos) were isolated from JEG-3 and HTR-8/SVneo cell 
culture supertantants. Nanoparticle Tracking Analysis (NTA) showed spherical vesicles in 
both populations (Fig. 25A insert). Median size of particles in the MP-enriched fractions was 
189 and 172 nm in JEG-3 and HTR-8/SVneo, respectively. Median size of particles in Exos-
enriched fractions was 116 nm in JEG-3 and 112 nm in HTR-8/SVneo cells (Fig. 25A). Particle 
diameter distribution ranged respectively from 50-530 nm in microparticles and 30-500nm in 
exosomal fractions (Fig. 25A). 
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4.3.1. Assessment of miR-141 in microparticles and exosomes isolated from cell 
culture supernatants 
Elevated miR-141 expression was observed in isolated microparticles and exosomes 
obtained from miR-141-mimic transfected cells when compared to those of non-transfected 
cells. Higher increase in miR-141 levels was detected in the microparticle fraction (~180-fold 
and ~120-fold increase, Fig. 25B) than in the exosomal fraction (~5.2-fold and ~5.3-fold 
increase, Fig. 25B) of transfected HTR-8/SVneo and JEG-3 cells, respectively. Levels of miR-
141 in the microparticle fraction was 1.5-fold higher in JEG-3 cells than in HTR-8/SVneo (Fig. 
25B) but similar expression was observed in the exosomal fraction of both cell lines (Fig. 
25B).  
 
Figure 25. Characterization of two fractions of extracellular vesicles (EMVs) isolated from cell 
line supernatants. Based on different isolation protocols, the fractions were exosomes (EXO) 
and microparticles (MP) enriched. A. Particle size distribution and concentration of EXO and 
MP enriched fractions from JEG-3 and HTR-8/SVneo cell supernatants. Representative 
nanoparticle tracking analysis (NTA) for EXO (black line) and MP (red line) enriched fractions 
isolated from HTR-8/SVneo cell supernatants. Insert: Light scatter from isolated particles. B. 
qRT-PCR analysis of miR-141 expression in EMVs isolated from cell line supernatants before 
transfection (MPCTR and EXOCTR) and after transfection with scrambled sequences (MPSCR and 
EXOSCR) or miR-141-mimic (MPmiR-141 and EXOmiR-141). MiR-141 expression is expressed as fold 
change ±SEM with RNU48 as endogenous control and normalized to JEG-3 MPCTR. 
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4.3.2. Trophoblastic cells do not auto-regulate invasion by secretion of miR-141-
containing microvesicles 
Non-transfected HTR-8-SVneo cells were seeded in a Matrigel assay chamber and then 
treated with isolated MPs or EXOs derived from cells which were non-transfected (CTR), 
transfected with miR-141 mimic (pre-miR-141) or with the respective non-genomic negative 
controls (pre-SCR). No significant changes were observed in the cell invasion capability of 
cells incubated with up to 100µl of any isolated MPs or EXOs (Fig. 26A). 
 
4.3.2.1. Intercellular transfer of extracellular vesicles containing miR-141  
Jurkat T cells were treated with increasing amounts of isolated MPs or EXOs from 
supernatans of non-transfected cells (CTR), cells transfected with miR-141 mimic (pre-miR-
141) or with the respective non-genomic negative controls (pre-SCR). A significant dose-
dependent reduction of Jurkat proliferation was observed after 48h of treatment with MPs 
and EXOs containing higher levels of miR-141 compared to that of basal levels. Treatment 
with high doses of EMVs reduced cell proliferation independently of the miR-141 content 
(Fig. 26B). 
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Figure 26. Intercellular communication mediated by microvesicles containing miR-141. 
Exosome- (EXO) and microparticle-enriched (MP) fractions were isolated from HTR-8/SVneo 
cell supernatants before (EXOCTR and MPCTR, respectively) and after transfection with 
scrambled non-genomic sequences (EXOSCR and MPSCR) or miR-141-mimic (MPmiR-141 and 
EXOmiR-141). A. Non-transfected HTR-8/SVneo cells were incubated with isolated 
microvesicles and relative invasion was assessed after 48h. B. After 24 h and 48 h treatment 
with isolated and differently treated MPs or EXOs, proliferation of Jurkat T cells was assessed 
by BrdU assays. All bars (in A and B) represent mean (n=3) ± SEM *p<0.05. 
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Chapter 5/ Discussion  
 
5.1. EGF in trophoblast model. 
Human pregnancy is considered a process where the mother´s immune system decides to 
tolerate and foster an incorporated, non-self, non-dangerous organism (tolerated semi-
allogenic). The success of pregnancy depends on a bidirectional “ feto-maternal dialogue”, 
where the “messages” that are “spoken” are relayed through signaling mediators, which are 
capable of transmitting a functional command to a target cell [47]. Although there have 
been a number of studies considering the potential role(s) played by these mediators, 
cytokines or growth factors, at the time of implantation, its complex nature requires further 
clarity. Understanding the physiological processes in pregnancy enables effective 
management of pregnancy disorders threatening the mother and her fetus.  
In the field of human reproduction, several investigations on different cell models have 
provided a large amount of information about different cytokines and growth factors and 
their association with pregnancy complications, such as preeclampsia and preterm delivery 
or recurrent miscarriage. Some are discussed in reviews, elucidating the important roles of 
EGF and LIF in trophoblast functions through a variety of intracellular pathways such as 
JAK/STAT and MAPK [47, 121, 122].  
EGF is a pivotal growth factor, which influences a variety of fundamental cell properties 
needed for normal pregnancy [47]. The importance of EGF has been demonstrated in vitro 
and in vivo. EGF is associated with promoting growth of the developing fetus in pregnant 
women [122, 123]. 
EGF can activate STAT1, STAT3 or STAT5 either simultaneously or individually in a cell type-
depended manner [29, 124, 125]. EGF treatment results in increase of only p-STAT3 in 
kidney tubular epithelial cells [126], but only p-STAT5 in U87 glioma cells [127]. In human 
breast cancer, STAT3 and STAT5 are activated simultaneously by EGF [125], while in 
squamous carcinoma cells, EGF activates STAT1 and STAT3 [128]. Previous studies in HTR-
8/SVneo cells demonstrated that EGF triggers STAT5 phosphorylation but does not induce 
phosphorylation of either STAT1 or STAT3 [29]. This study goes in line with our results 
demonstrating activation of STAT5 but not of STAT3 after EGF treatment in HTR-8/SVneo 
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and JAR cells. These observations suggest that in trophoblast cells, EGF effects are mediated 
via STAT5 rather than via STAT3.  
STATs are usually located in the cytoplasm but upon activation, they become 
phosphorylated, dimerize, and translocate into the nucleus where they bind to DNA and 
modulate gene expression [129]. Our results demonstrated high expression of STAT5B mRNA 
in isolated trophoblast cells which was similar to that of HTR8/SVneo but significantly lower 
in JAR cells. The protocol used in this study allows the isolation of extravillous trophoblast 
cells which are physiologically responsible for invasion during placenta formation [116]. The 
results highlight the importance of STAT5 during trophoblast invasion and demonstrate the 
suitability of the used cell lines models. 
Using JAR and HTR-8/SVneo cells as models, we demonstrated that EGF effects are mediated 
via STAT5. The localization of p-STAT5 was in the nuclei of both cell lines after EGF 
treatment. These observations suggest activation of STAT5 after EGF stimulation, which was 
confirmed by Western blotting and immunocytochemistry. Not in line with these results, 
STAT5 DNA-binding activity was not altered by stimulation with EGF. We could measure only 
a low constitutive STAT5 DNA-binding activity. These results are congruent with previous 
observations demonstrating that some biological functions mediated by STAT5 are 
independent of its DNA binding and may be the result of consequent activation of other 
transcriptional factors [127], thus, the specific intracellular mechanism remains to be 
elucidated.   
After confirmation of its EGF-induced activation, STAT5 silencing was conducted in both cell 
lines by using specific siRNA followed by EGF-stimulation. The expression of STAT5 was 
silenced by ~70%, as confirmed by Western blotting. Subsequently, viability, proliferation 
and invasion were analyzed.  
The activation of different STATs depends on cell-type and stimuli. For this reason, upon EGF 
stimulation, cell functions vary between the different cell lines. In our study, EGF increases 
cell viability in both cell lines as assessed by MTS, and STAT5 silencing resulted in a decrease. 
However, JAR proliferation was not significantly altered after stimulation with EGF as 
assessed by BrdU assays and the effect in HTR-8/SVneo cells was lower than that observed 
by MTS assay. The MTS assay is often used as a proliferation test and thus, the dissimilarities 
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observed here may be due to differences in the sensibility and applicability of these assays. 
When STAT5 expression is silenced, the effect of EGF on cell viability is lost which 
demonstrates involvement of STAT5 in the increased cell viability induced by EGF. Other 
intracellular cascades like MAPK can also mediate EGF effects suggesting possible cross-talks 
that should be further investigated.  
In the present work, enhanced invasiveness of HTR-8/SVneo cells after EGF treatment has 
been demonstrated. However, when STAT5 gene expression is silenced, EGF does not 
increase invasion although the STAT5 DNA-binding activity remains unaltered. This result is 
consistent with another study, where EGF enhances U87 glioma cell invasion via a 
mechanism independent of STAT5 DNA-binding [127]. 
In our hands, JAR cell invasion is not altered after EGF treatment. Previously, it was reported 
that EGF enhances invasion in JAR cells [130, 131]. This discrepancy may be explained by 
differences between methods. In our current study, nuclei of invasive cells have been 
stained with violet crystal after 24 h, while in the previous study, invaded cells were 
indirectly quantified by reduction of tetrazolium salts after 48-72 h [131].  
Altogether, our data suggest that the intracellular mechanisms controlling invasion induced 
by EGF differ between JAR and HTR-8/SVneo cells. These results can be explained, as 
mentioned before, by the different origin of cell lines: JAR is a choriocarcinoma cell line 
while HTR-8/SVneo is a transformed cell line from first trimester trophoblast cells [132]. Also 
other investigations described major differences between HTR-8/SVneo and 
choriocarcinoma cell lines including dissimilarities in their protein and gene expression 
profiling [75, 133, 134]. Further studies are necessary for understanding the mechanisms of 
invasion in the different cell lines.  
In breast cancer cells, STAT5 targets genes that promote cell survival and proliferation 
including Heat Shock Protein 90-A (HSP90A), IGF and cyclin D1 33. These molecules are also 
expressed by trophoblast cells and regulate cell cycle; this point should be further 
investigated. 
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5.2. MiRNA Expression in trophoblastic cell lines  
MiRNAs are considered as factors of epigenetic processes of major relevance during 
embryogenesis, in special in gamete development, pre-implantation embryo development, 
and placentation [135]. Additionally, some of their main functions are the control of genes 
associated with inflammatory responses [136] and regulation of immune tolerance-
associated genes, such as HLA-G [137]. Therefore, in recent years, the impact of miRNAs has 
attracted attention in studies on reproduction and human pregnancy. Many investigations 
have provided information about miRNA profiles and helped to decipher their function and 
regulation. However, miRNA landscape in reproduction is still incipient and further 
investigations are necessary.  
In several publications we have reviewed the knowledge on miRNA, including their potential 
role in evolution. For instance, microRNAs ascended early in evolution, causing that 
processes of biogenesis and target recognition differ significantly between organisms like 
plants and animals. For example, only miR-100 is found to be shared by all major animal 
groups except sponges [138]. The investigation on miRNA evolution led to the proposal of 
three bursts of miRNAs. One of them based in the bilaterian lineage, the second in the 
vertebrate lineage and, finally, a third miRNA expansion in the lineage leading to eutherian 
species. These events generated a correlation between the morphological complexity of a 
given species and the number of encoded miRNA genes in its genome. To the best of our 
knowledge, thus far, according to the public miRNA database miRBase, the genome 
comprises more of 358 miRNA genes for zebrafish, 720 in mouse and more of 1424 in human 
[139]. However, new miRNA data is accumulating rapidly, but validation of target genes is far 
from being completed [67].  
To elucidate the mechanisms involved in miRNA evolution and to infer their functionality, it 
requires the recogniton of homologous sequences within species and the extrapolation of 
large datasets of miRNAs and targets is imperative. Depending on how miRNA-mRNA 
interactions affect the organism, three different groups can be distinguished: positive 
selection, neutral selection and negative selection. The majority of miRNA targets resulted 
from neutral or negative selection reflected by the fact that their targets are not conserved 
[140]. By searching for orthologs of human mature miRNAs expressed in the placenta, 10 
human-specific-miRNAs and 12 further miRNAs with human-specific seed sequences were 
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identified [67]. Interestingly, most of these miRNAs exhibit low expression but miR-941 
showed remarkable abundance in different tissues. Many studies have been performed on 
miR-941 and revealed its expression in primary first trimester trophoblast cells and its 
absence in third trimester cells. Additionally, miR-941 is expressed in trophoblast cell lines of 
first trimester, but not by ACH-3P cells, which is a hybrid of choriocarcinoma cells with first 
treimester trophoblast. However, the specific effects of miR-941 in the placenta are still 
unknown [67]. 
The expression of numerous placenta-associated miRNAs can be mainly localized within the 
clusters C14MC, C19MC and miR-371-3. It may be hypothesized that the evolution of 
eutherian species was facilitated by C14MC and that C19MC which may be related with 
human primate embryo development [80, 141]. The information published in our reviews, 
revealed that these clusters are conserved in mammals only [142] and are highly expressed 
in human embryonic stem cells (ESCs). They are essential for cell cycle maintenance [143] 
and for regulation of proliferation and apoptosis [144]. 
As mentioned before, some C14MC miRNAs are relevant for the development of the 
placenta. Some of them have been conserved in all placental mammals, others are restricted 
to smaller or larger groups of species. In this study miR-134 belonging to C14MC was also 
investigated. MiR-134 is specifically associated with pregnancy since it is high expressed in 
placental tissue and in umbilical cord but it is low expressed in nonpregnant women [85]. 
Our results show that inhibition of miR-134 significantly suppresses cell invasion whilst miR-
134 overexpression decreases proliferation only in HTR-8/SVneo cells which suggest an 
important function during placenta development. However, its specific functions in 
controlling trophoblast cells should be further investigated. 
 These placental miRNAs may have the potential for becoming novel biomarkers for 
prediction and detection of pathologies in pregnancy. For this reason, it is of crucial 
importance to fully understand the expression patterns in all pregnancy-disorders including 
preeclampsia, gestational diabetes, intrauterine growth restriction and low birth weight. 
Having the respective information it may be possible to generate tools for the prevention or 
treatment of such diseases. 
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Although the scenario is promising, the search for potential novel biomarkers is hallmarked 
by limitations and problems. The incipient information about miRNAs and the differences 
between in vivo and in vitro models leads to a delay in the process of drug development. 
Further, the inappropriate technology for the modulation of miRNA expression and hurdles 
such as drug delivery to the right organs or tissues are some of the problems we are facing. 
Despite these hurdles, many investigations have been successful, and therapeutic programs 
are progressing and indicate the potential of miRNAs for diagnosis and therapy of various 
human diseases [103].  
Expression of miRNAs in placental tissue changes dynamically with the gestational age [73, 
74, 101, 145] and this change is reflected in vesicles released by several cell types including 
trophoblast cells [71, 99]. Among others, miR-141 is considered a pregnancy-associated 
miRNA because it is found at concentrations 10-fold higher in placental tissue than in 
maternal plasma, its expression increases constantly through pregnancy, and 24 h post-
delivery, it cannot be longer detected in maternal plasma [100]. Recently, miR-141 has been 
detected in trophoblast extracellular vesicles suggesting an important role in the 
communication between placenta and the maternal system [146]. These observations 
suggest miR-141 as a pregnancy biomarker which may be expected to be dysregulated in 
pregnancy disorders as PE. 
Despite the small sample number, this study included a homogeneous group of severe PE 
and their counterpart of normal pregnancies (Table 1). In our hands, an up-regulation of 
miR-141 was observed in preeclamptic placenta compared with those from normal 
pregnancies. These data agree with previous reports showing up-regulation of miR-141 in 
placenta and maternal plasma of severe preeclampsia patients compared with normal 
pregnancies [145, 147].  
In the cell lines used as trophoblast models, HTR-8/SVneo and JEG-3 cells, miR-141 was 
similarly expressed but compared to normal or PE placenta tissues, it was significantly lower. 
This confirms our previous report, where we have demonstrated lower miR-141 expression 
in four cell lines when compared with isolated 1st and 3rd trimester trophoblast cells [75] .  
Few studies have been published about the influence of miR-141 on functions in 
trophoblastic cell lines [73]. However, some investigations in other types of cell lines 
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revealed that miR-141 regulates functions and plays an important role in tumorigenesis or 
acts as oncogene. For example, miR-141 has been studied in ovarian cancer cells [148, 149], 
colon cancer [150], renal cell carcinoma [151], breast cancer [152], pancreatic cancer [153], 
nasopharyngeal carcinoma [154] and gastric cancer [155] but its exact function is still not 
clarified. 
Consequently the contribution of miR-141 to trophoblast cell proliferation and invasion was 
investigated. Expression of miR-141 was effectively enhanced after transfection with miR-
141-mimic and successfully inhibited after transfection with miR-141-antagomir, evidencing 
that this method allows analysis of gain- and loss-of-function. Our study showed that miR-
141-antagomir inhibits the viability of JEG-3 cells, while miR-141-mimic did not further 
induce viability. This may be due to the constitutive abundance of endogenous miR-141 in 
the JEG-3 cells whose function cannot be exhacerbated by additional miR-141 expression. A 
prior study has also reported over 50% decreased in cell viability after miR-141 inhibition 
which is much higher than the observed in this study. This discrepancy may be explained by 
the differences between the methods. In our current study, we used Oligofectamine 
reagent, while in the previous study, the transfection was performed using Nanofectin [73]. 
In HTR-8/SVneo cells, no significant differences in viability were detectable after miR-141 
over-esxpression or inhibition. This difference between our models, JEG-3 and HTR-8/SVneo 
cells, may be explained by their different origin. HTR-8/SVneo cells have been immortalized 
by a vector transformation that induces uncontrolled amplification and splicing of viral DNA 
resulting in a heterogeneous genotype while JEG-3 is a choriocarcinoma cell line without 
virus-treatment [75].  
The results suggest that miR-141 is involved in the viability of trophoblastic cells, and thus, in 
placental development. However, the results obtained by MTS assays do not correspond 
with those obtained by BrdU assays. This discrepancy may be due to the distinct analyzed 
factors: MTS assays analyze mitochondrial functions in contrast to BrdU assays, which 
assesses BrdU incorporation into newly synthesized DNA. Further studies are necessary for 
understanding the mechanisms in the different trophoblastic cell lines. 
We have shown that inhibition of miR-141 significantly suppresses invasion in both cell lines, 
JEG-3 and HTR-8/SVneo. Overexpression of miR-141 promotes the invasion only in HTR-
8/SVneo cells. Our data are in accordance with those of Zhang and colleagues [154] who 
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showed that in nasopharyngeal carcinoma (NPC) cells treated with miR-141 inhibitor the 
number of cells migrating through Matrigel decreased significantly. However, our report is in 
contrast to other studies suggesting that overexpression of miR-141 suppresses cell invasion 
and inhibition of miR-141 promotes invasion in pancreatic cancer [153] and gastric cancer 
[155]. These opposing findings substantiate the hypothesis that miR-141 has a 
heterogeneous role and cell-specific response.  
Despite the fact that the PE etiology is still widely unclear, previous studies indicate that this 
disorder may be caused by the imbalanced immune system at the maternal–fetal interface 
[156] affecting the correct development of trophoblast cells [157]. Moreover, studies have 
shown that PE results in a shift in angiogenesis and anti-angiogenic factors toward a 
maladaptive placental circulation [158].  
Since miR-141 is altered in placentas from preeclamptic women and may influence 
proliferation and invasion in trophoblastic cells, we decided to evaluate the function of 
extracellular vesicles (EMVs) containing miR-141. Our results demonstrate that trophoblast 
cells released exosomes and microparticles containing miR-141 under normal conditions. 
After transfection with precursor miR-141, HTR-8/SVneo cells released microvesicles 
containing elevated levels of mature miR-141. This demonstrates that the cells had 
processed the precursor miR-141 to its mature form through the RNA interference pathway 
and packed it into microvesicles. This result emphasizes the importance of miR-141 in the 
intercellular communication and supports its possible use as biological biomarker. 
The next step was to evaluate if miR-141-containing EMVs released by trophoblastic cells 
regulate functions in recipient cells of the same type or if the intercellular communication 
occurs between cells at a distance and of different origins. We did not detect effects of EMVs 
on invasion of trophoblastic cell lines despite of using different concentrations (50 or 100µl). 
This observation suggests that intercellular communication does not occur between similar 
cells. Therefore, we hypothesize that trophoblast-derived EMVs affect other cell types. As 
numerous studies reporthigh levels of circulating EMVs (especially from T cells) in plasma of 
preeclamptic women [109] and trophoblast-derived EMVs contain miRNA and display 
immunosuppressive properties [159], we decided to analyze their effectson human T 
lymphocytes (Jurkat). Our data show a decrease in cell proliferation of T cells in presence of 
MPs and EXO confirming the hypothesis that intercellular communication by transferring 
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microRNA frotm trophoblast cells to immune cells occurs. In addition, we observed a 
cytotoxic effect induced by high concentrations of trophoblast EMVs.  
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Chapter 6/ Conclusions  
 
EGF plays an important role in regulation of trophoblast. Our data demonstrate that 
activation of STAT5 in response to EGF promotes cell viability and invasion in trophoblastic 
cell lines. Understanding the cellular processes induced by this factor might provide relevant 
information for better understanding various pregnancy-associated diseases. However, we 
face the problem of selecting cell lines as models for the study of human embryo 
implantation and placentation.  
Numerous members of the miRNA clusters C14MC and C19MC or the miR-200 family can be 
detected in maternal serum and seem to reflect the state of the placenta potentially having 
the capacity of becoming novel biomarkers indicating pregnancy disorders. Targeting or 
mimicking these miRNAs may lead to novel therapeutic concepts.  
Alteration in cellular functions after the inhibition or overexpression suggests that miR-134 
may play an important role in the control of cell proliferation and invasion of trophoblast 
cells during the first trimester of pregnancy.  
MiR-141 has regulatory functions in trophoblastic cells and is upregulated in PE It is packed 
into to extracellular vesicles (EMVs) which serve for intercellular communication with distant 
cells, including immune cells. This communication may contribute to the materno-fetal 
immunotolerance. Overall, theresults indicate an essential role of miR-141 and EMVs in 
pathological and physiological conditions in pregnancy. 
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Chapter 7/ Summary 
 
Trophoblasts are key cells in the development of mammal placenta. One of their functions in 
humans is anchoring the fetal compartment in the maternal decidua which is achieved by 
the invading trophoblast cells. This invasion is limited in space and time and its disorders 
may lead to several pregnancy complications. Previous investigations have revealed that 
trophoblast invasion is strongly influenced by cytokines and growth factors. One of the most 
relevant is Epidermal Growth Factor (EGF), which is able to influence positively or negatively 
a variety of fundamental cell properties. Growth factors and cytokines trigger their effects 
through several transcription pathways such as  Extracellular-signal Regulated Kinase (ERK) 
and the Janus Kinase-Signal Transducers and Activators of Transcription (JAK/STAT). 
Although several studies have demonstrated the role of EGF and STAT5 in the regulation of 
trophoblast behavior, the interaction between both molecules has not yet been 
investigated. Recent studies have demonstrated STATs are also regulated by microRNAs 
(miRNAs). Increasing evidence demonstrates that miRNAs are packed and released by 
trophoblast cells in extracellular membrane vesicles (EMVs) which appear to mediate 
intercellular communication. Some miRNAs are expressed abundantly in normal placenta 
and their dysregulation may be involved in the development of pregnancy diseases like 
preeclampsia (PE).  
Aim of this study was to examine the activation of STAT3 and STAT5 by EGF in different 
trophoblastic cell lines and the effects on cell proliferation, viability and invasion. 
Additionally, the functions of miR-134 and miR-141 in controlling proliferation and invasion 
of trophoblastic cell lines should be investigated. The expression of miR-141 should be 
analyzed in trophoblastic EMVs as well as their effects on immune cells.  Finally, the 
concentration of miR-141 in tissues of normal and preeclamptic placentas was analyzed. 
The functions of different cell types have been investigated mainly by MTS- (viability), BrdU- 
(proliferation) and Matrigel (invasion) assays. RNA and miRNA expression has been analyzed 
by RT-qPCR, protein expression by Western blotting. STAT5 and miRNAs have been 
chemically inhibited. MiRNAs have been overexpressed by transfection with their precursor 
form. EMVs have been isolated from JEG-3 and HTR8/SVneo immortalized first trimester 
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trophoblast cells and analyzed by NanoSight and RT-qPCR. For analyses of primary cells and 
tissues placentas from normal and PE pregnancies have been used. 
Isolated trophoblasts express high levels of STAT5B, which is similar to HTR8/SVneo cells. 
Expression in JAR choriocarcinoma cells was significantly lower. EGF-mediated STAT5 
activation increased proliferation and viability in both cell lines. STAT5 knock-down resulted 
in significant decrease of cell viability induced by EGF. Only in HTR8/SVneo cells, invasion 
decreased after STAT5 silencing and this effect could not be rescued by further addition of 
EGF. These results demonstrate that STAT5 activated by EGF constitutes an important 
cascade for the regulation of cell proliferation and invasion in trophoblast cells.  
Inhibition of miR-134 significantly suppressed invasion of trophoblast and choriocarcinoma 
cell lines whilst miR-134 overexpression decreased proliferation only in HTR-8/SVneo cells 
which suggests a role of miR-134 in placenta development.  
MiR-141 was up-regulated in placentas from preeclampsia patients compared to normal 
pregnancies. Cell lines express similar miR-141 levels and this expression was successfully 
inhibited or over-expressed by transient transfection. Inhibition of miR-141 resulted in 
decreased JEG-3 viability and reduced invasion capability of JEG-3 and HTR8/SVneo cell lines. 
After overexpression of miR-141, HTR-8/SVneo cells secreted EVs with increased miR-141 
content. Incubation of isolated EVs with of non-transfected HTR8/SVneo cells did not alter 
invasion, incubation with Jurkat T cells reduced their proliferation. 
In conclusion, the EGF-STAT5 signalling cascade controls fundamental trophoblast functions 
important for normal placentation. MiR-141 regulates trophoblast invasion and may play an 
important role in the intracellular communication by a paracrine mechanism based on 
secretion of extracellular vesicles. It appears also elevated in PE patients and may have 
potential for serving as a new biomarker. 
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Chapter 8/ Zusammenfassung 
 
Trophoblastzellen haben Schlüsselfunktionen in der Placenta. Eine dieser Funktionen in der 
menschlichen Placenta ist die Verankerung des fetalen Gewebes in der mütterlichen 
Decidua, was durch die Invasion der Trophoblastzellen gewährleistet wird. Die Invasion ist 
zeitlich und räumlich begrenzt, ihre Störungen können zu verschiedenen 
Schwangerschaftskomplikationen führen. Frühere Studien haben gezeigt, dass 
Trophoblastinvasion durch  Zytokine und Wachstumsfaktoren kontrolliert wird, wie zum 
Beispiel durch Epidermal Growth Factor (EGF), der eine Reihe von Zellfunktionen beeinflusst. 
Wachstumsfaktoren und Zytokine induzieren ihre Effekte über verschiedene intrazelluläre 
Signalkaskaden wie den Extracellular-signal Regulated Kinase (ERK)- und den Janus Kinase-
Signal Transducers and Activators of Transcription (JAK/STAT)-Signalweg. Obwohl eine 
Beteiligung von EGF und STAT5 an der Regulation von Trophoblastzellen beschrieben wurde, 
wurden die Interaktionen zwischen beiden noch nicht untersucht. Neuere Studien berichten 
über die Regulation von STAT-Molekülen durch microRNAs (miRNAs). Es gibt zunehmend 
Hinweise, dass miRNAs von Trophoblastzellen in extrazelluläre Mikrovesikel (EMVs) 
eingeschleust werden, die zur interzellulären Kommunikation in die Zirkulation freigesetzt 
werden. Einige miRNAs sind in der Placenta hoch exprimiert und zahlreiche 
Schwangerschaftsstörungen, wie die Präeklampsie (PE), gehen mit einer Fehlregulation der 
miRNAs einher. Bislang wurde jedoch wenig über die konkrete Rolle von miRNAs bei der 
Regulation fundamentaler Trophoblastfunktionen wie Proliferation, Migration oder Invasion 
berichtet. Das Ziel dieser Arbeit war die Aktivierung von STAT3 und STAT5 durch EGF in 
verschiedenen trophoblastären Zelllinien zu untersuchen und die Effekte in Bezug auf 
Proliferation. Außerdem sollten Funktionen von miR-134 und miR-141 bezüglich der 
Proliferation und Invasion von trophoblastären Zelllinien untersucht werden. Die Expression 
von  miR-141 sollte in trophoblastären EMVs untersucht werden sowie ihre Effekte auf 
Immunzellen. Schließlich sollte die Expression von miR-141 in gesunden und PE Placenten 
verglichen werden. 
Die Funktionen der verschiedenen Zelltypen wurden vorwiegend mittels MTS- (Viabilität), 
BrdU- (Proliferation) und Matrigel- (Invasion) Assays untersucht. RNA und miRNA Expression 
wurde mittels RT-qPCR gemessen, die Protein Expression mittels Western blotting. STAT5 
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und die miRNAs wurden chemisch inhibiert. MiRNAs wurden durch Transfektion mit ihrer 
Precursor-Form überexprimiert. EMVs wurden aus JEG-3 (Chorionkarzinom)-Zellen und 
HTR8/SVneo (immortalisierte Ersttrimester Trophoblast)-Zellen isoliert und mittels 
NanoSight und RT-qPCR analysiert. Zur Untersuchung von Primärzellen wurden Plazenten 
aus gesunden und PE Schwangerschaften genutzt.  
Die Expression von STAT5B ist hoch in isolierten Trophoblastzellen, ähnlich wie in 
HTR8/SVneo-Zellen. Die Expression in JAR-Chorionkarzinom-Zellen war deutlich niedriger. 
Die EGF-induzierte STAT5-Aktivierung steigert die Proliferation und Viabilität beider 
Zelllinien. Eine STAT5-Inhibierung bewirkt eine signifikante Reduktion der EGF-induzierten 
erhöhten Viabilität. Nur in HTR8/SVneo-Zellen ist die Invasivität nach STAT5-Inhibierung 
vermindert und kann durch Stimulierung mit EGF nicht wieder gesteigert werden. Diese 
Ergebnisse zeigen, dass die STAT5-Aktivierung durch EGF ein wichtiges Signal für die 
Regulation der Proliferation und Invasion trophoblastärer Zellen darstellt.  
Die Inhibierung von miR-134 supprimiert die Invasivität von HTR8/SVneo-Zellen, während 
die Überexpression deren Proliferation hemmt. Diese Ergebnisse unterstreichen eine 
Beteiligung von miR-134 an der Regulation der Placentation.   
MiR-141 ist in PE-Plazenten im Vergleich zu gesunden Plazenten erhöht. Trophoblastäre 
Zelllinien (JEG-3, HTR8/SVneo) exprimieren ähnliche miR-141-Konzentrationen, die chemisch 
inhibiert oder durch Transfektion erhöht werden konnten. Die Inhibierung von miR-141 
bewirkt eine Reduktion der Viabilität von JEG-3-Zellen sowie eine verminderte Invasivität 
beider Zelllinien. Nach Transfektion von HTR8/SVneo-Zellen mit Precursor-miR-141, haben 
diese EMVs mit signifikant erhöhten miR-141-Konzentrationen sezerniert, die isoliert werden 
konnten. Die Inkubation von nicht-transfizierten Zellen mit diesen EMVs beeinflusst nicht 
deren Invasivität. EMVs mit erhöhter miR-141-Konzentration vermindern die Proliferation 
von Jurkat T-Zellen.  
Es lässt sich schlussfolgern, dass die EGF-STAT5 Signalkaskade für die Plazentation 
fundamentale Trophoblastfunktionen kontrolliert. MiR-141 reguliert die Trophoblastinvasion 
und scheint in EMVs verpackt der Kommunikation mit Immunzellen durch parakrine 
Mechanismen zu dienen. MiR-141 ist in PE Patientinnen erhöht und hat Potenzial 
diesbezüglich als neuer Biomarker eingesetzt zu werden. 
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